Biomolecules and nanostructures
The Optical Sciences group studies the interaction of light and matter at the nanoscale.
We do this by exploring ways to shape light and its environment. It's what we call
active and passive control. Our current focus is on the interaction of light with
biomolecules and nanostructures. We are part of Twente
University's Department of Science and Technology and member of the
Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake
Marlous Arjaans, Thijs H. Oude Munnink, Sjoukje F. Oosting, Anton G.T. Terwisscha van Scheltinga, Jourik A. Gietema, Erik T Garbacik, Hetty Timmer-Bosscha, Marjolijn N. Lub-de Hooge, Carolina P. Schroder, and Elisabeth G.E. de Vries
June 1, 2013 73:3347-3355 Published Online April 11, 2013;
In solid tumors, angiogenesis occurs in the setting of a defective vasculature and impaired lymphatic drainage that is associated with increased vascular permeability and enhanced tumor permeability. These universal aspects of the tumor microenvironment can have a marked influence on intratumoral drug delivery that may often be underappreciated. In this study, we investigated the effect of blood vessel normalization in tumors by the antiangiogenic drug bevacizumab on antibody uptake by tumors. In mouse xenograft models of human ovarian and esophageal cancer (SKOV-3 and OE19), we evaluated antibody uptake in tumors by PET imaging 24 and 144 hours after injection of 89Zr-trastuzumab (SKOV-3 and OE19), 89Zr-bevacizumab (SKOV-3) or 89Zr-IgG (SKOV-3) before or after treatment with bevacizumab. Intratumor distribution was assessed by fluorescence microscopy along with mean vascular density (MVD) and vessel normalization. Notably, bevacizumab treatment decreased tumor uptake and intratumoral accumulation compared to baseline in the tumor models relative to controls. Bevacizumab treatment also reduced MVD in tumors and increased vessel pericyte coverage. These findings are clinically important, suggesting caution in designing combinatorial trials with therapeutic antibodies due to a possible reduction in tumoral accumulation that may be caused by bevacizumab co-treatment.